O2 Serious infection, including severe COVID19, seems not to be a major clinical problem in patients with systemic lupus erythematosus treated with Belimumab, according the data from a large multicenter cohort

MLA

Íñigo Rúa-Figueroa, et al. “O2 Serious Infection, Including Severe COVID19, Seems Not to Be a Major Clinical Problem in Patients with Systemic Lupus Erythematosus Treated with Belimumab, According the Data from a Large Multicenter Cohort.” Lupus Science and Medicine, vol. 11, no. Suppl 1, Mar. 2024. EBSCOhost, https://doi.org/10.1136/lupus-2024-el.12.

APA

Íñigo Rúa-Figueroa, José A Gómez-Puerta, Javier Narváez, Eva Tomero, Clara Moriano, Elvira Díez Álvarez, Consuelo Ramos Giráldez, Maria Angeles Blazquez Cañamero, Maria Galindo Izquierdo, Jaime Calvo Alen, Jose Maria Pego Reigosa, Irene Altabás González, Beatriz Frade-Sosa, Margarida Vasques Rocha, Andrea Hernández-Martín, Paola Vidal-Montal, Eleonora Penzo, Marta de la Rubia Navarro, José Andrés Román Ivorra, … Alejandro Muñoz Jiménez. (2024). O2 Serious infection, including severe COVID19, seems not to be a major clinical problem in patients with systemic lupus erythematosus treated with Belimumab, according the data from a large multicenter cohort. Lupus Science and Medicine, 11(Suppl 1). https://doi.org/10.1136/lupus-2024-el.12

Chicago

Íñigo Rúa-Figueroa, José A Gómez-Puerta, Javier Narváez, Eva Tomero, Clara Moriano, Elvira Díez Álvarez, Consuelo Ramos Giráldez, et al. 2024. “O2 Serious Infection, Including Severe COVID19, Seems Not to Be a Major Clinical Problem in Patients with Systemic Lupus Erythematosus Treated with Belimumab, According the Data from a Large Multicenter Cohort.” Lupus Science and Medicine 11 (Suppl 1). doi:10.1136/lupus-2024-el.12.